FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Open forum infectious diseases2020; 7(9); ofaa359; doi: 10.1093/ofid/ofaa359

Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral Infections: A Follow-up Study 5 Years After an Outbreak in Panama.

Abstract: Human cases of Madariaga virus (MADV) infection were first detected during an outbreak in 2010 in eastern Panama, where Venezuelan equine encephalitis virus (VEEV) also circulates. Little is known about the long-term consequences of either alphavirus infection. Methods: A follow-up study of the 2010 outbreak was undertaken in 2015. An additional survey was carried out 2 weeks after a separate 2017 alphavirus outbreak in a neighboring population in eastern Panama. Serological studies and statistical analyses were undertaken in both populations. Results: Among the originally alphavirus-seronegative participants (n = 35 of 65), seroconversion was observed at a rate of 14.3% (95% CI, 4.8%-30.3%) for MADV and 8.6% (95% CI, 1.8%-23.1%) for VEEV over 5 years. Among the originally MADV-seropositive participants (n = 14 of 65), VEEV seroconversion occurred in 35.7% (95% CI, 12.8%-64.9%). In the VEEV-seropositive participants (n = 16 of 65), MADV seroconversion occurred in 6.3% (95% CI, 0.2%-30.2%). MADV seroreversion was observed in 14.3% (95% CI, 1.8%-42.8%) of those who were originally seropositive in 2010. VEEV seroconversion in the baseline MADV-seropositive participants was significantly higher than in alphavirus-negative participants. In the population sampled in 2017, MADV and VEEV seroprevalence was 13.2% and 16.8%, respectively. Memory loss, insomnia, irritability, and seizures were reported significantly more frequently in alphavirus-seropositive participants than in seronegative participants. Conclusions: High rates of seroconversion to MADV and VEEV over 5 years suggest frequent circulation of both viruses in Panama. Enhanced susceptibility to VEEV infection may be conferred by MADV infection. We provide evidence of persistent neurologic symptoms up to 5 years following MADV and VEEV exposure.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Get Full Text
Publication Date: 2020-08-20 PubMed ID: 33005697PubMed Central: PMC7518370DOI: 10.1093/ofid/ofaa359Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the long-term effects of Madariaga virus (MADV) and Venezuelan equine encephalitis virus (VEEV) infections in Panama, observed over a period of 5 years since an outbreak in 2010. The study suggests regular circulation of both viruses in Panama, possible exacerbation of VEEV infection by previous MADV infection, and persisting neurological symptoms following exposure to the viruses.

Research Methodology

  • The researchers conducted a follow-up study five years after the 2010 outbreak and an additional assessment two weeks post a separate spring of alphavirus infection in 2017.
  • Serological studies were undertaken for both populations to look at antibodies resulting from exposure to the viruses.
  • Statistical analysis was used to understand the patterns and rates of seroconversion (the period when a specific antibody enters the bloodstream, indicating an immune response to an infection).

Research Findings

  • Among 35 participants who were initially negative for alphavirus infection, a 14.3% rate of seroconversion for MADV and an 8.6% rate for VEEV was found over five years.
  • The rate of VEEV seroconversion for those initially positive for MADV was significantly higher (35.7%) than that for individuals initially negative for any alphavirus infection.
  • The study also found that among participants initially seropositive for VEEV, 6.3% seroconverted for MADV.
  • It was further noted that 14.3% of the participants originally seropositive for MADV in 2010 demonstrated seroreversion, which is the loss of detectable antibodies in the blood.
  • In the population evaluated in 2017, rates of MADV and VEEV seroprevalence were found to be 13.2% and 16.8%, respectively.
  • The researchers discovered that memory loss, insomnia, irritability, and seizures were more frequently reported in participants who had been seropositive for alphaviruses.

Research Conclusions

  • The high rates of seroconversion for both MADV and VEEV indicate that both viruses circulate frequently in Panama.
  • Previous MADV infection could potentially make individuals more susceptible to VEEV infection, but additional research is required to understand this relationship further.
  • The researchers discovered that neurological symptoms could persist up to 5 years after exposure to MADV and VEEV, necessitating greater attention from the medical community.

Cite This Article

APA
Carrera JP, Pittí Y, Molares-Martínez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I, Galué J, Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly CA, Vittor AY. (2020). Clinical and Serological Findings of Madariaga and Venezuelan Equine Encephalitis Viral Infections: A Follow-up Study 5 Years After an Outbreak in Panama. Open Forum Infect Dis, 7(9), ofaa359. https://doi.org/10.1093/ofid/ofaa359

Publication

Open forum infectious diseases
ISSN: 2328-8957
NlmUniqueID: 101637045
Country: United States
Language: English
Volume: 7
Issue: 9
Pages: ofaa359

Researcher Affiliations

Carrera, Jean-Paul
  • Department of Zoology, University of Oxford, Oxford, UK.
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Pittí, Yaneth
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Molares-Martínez, Juan C
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Casal, Eric
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Pereyra-Elias, Reneé
  • National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Saenz, Lisseth
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Guerrero, Isela
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Galué, Josefrancisco
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Rodriguez-Alvarez, Fatima
  • Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Jackman, Carmela
  • Department of Epidemiology, Ministry of Health, Panama, Panama.
Pascale, Juan Miguel
  • Clinical Research Unit, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Armien, Blas
  • Department of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama.
Weaver, Scott C
  • Institute for Human Infection and Immunity, Department of Microbiology and Immunology, Department of Pathology, and World Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, USA.
Donnelly, Christl A
  • MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, Imperial College London, London, UK.
  • Department of Statistics, University of Oxford, Oxford, UK.
Vittor, Amy Y
  • Division of Infectious Disease and Global Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA.

Grant Funding

  • MR/R015600/1 / Medical Research Council
  • R24 AI120942 / NIAID NIH HHS

References

This article includes 33 references
  1. Navarro J-C, Carrera J-P, Liria J. Alphaviruses in Latin America and the introduction of chikungunya virus. In: Ludert, JE, Pujol F, Arbiza J, eds. Human Virology in Latin America. Cham, Switzerland: Springer International Publishing; 2017:169–92.
  2. Aguilar PV, Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC. Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella. Future Virol 2011; 6:721–40.
    pmc: PMC3134406pubmed: 21765860
  3. Powers AM, Oberste MS, Brault AC. Repeated emergence of epidemic/epizootic Venezuelan equine encephalitis from a single genotype of enzootic subtype ID virus. J Virol 1997; 71:6697–705.
    pmc: PMC191949pubmed: 9261393
  4. Vittor AY, Armien B, Gonzalez P. Epidemiology of emergent Madariaga encephalitis in a region with endemic Venezuelan equine encephalitis: initial host studies and human cross-sectional study in Darien, Panama. PLoS Neglect Trop Dis 2016; 10:e0004554.
    pmc: PMC4839771pubmed: 27101567
  5. Carrera J-PJ-P, Forrester N, Wang E. Eastern equine encephalitis in Latin America. New Eng J Med 2013; 369:732–44.
    pmc: PMC3839813pubmed: 23964935
  6. Bowen GS, Fashinell TR, Dean PB, Gregg MB. Clinical aspects of human Venezuelan equine encephalitis in Texas. Bull Pan Am Health Organ 1976; 10:46–57.
    pubmed: 949558
  7. Bhatt S, Gething PW, Brady OJ. The global distribution and burden of dengue. Nature 2013; 496:504-7.
    pmc: PMC3651993pubmed: 23563266
  8. Rivas F, Diaz LA, Cardenas VM. Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995. J Infect Dis 1997; 175:828-32.
    pubmed: 9086137
  9. Johnson KM, Shelokov A, Peralta PH, Dammin GJ, Young NA. Recovery of Venezuelan equine encephalomyelitis virus in Panama. A fatal case in man. Am J Trop Med Hyg 1968; 17:432-40.
    pubmed: 5690051
  10. Vilcarromero S, Laguna-Torres VA, Fernández C. Venezuelan equine encephalitis and upper gastrointestinal bleeding in child. Emerg Infect Dis 2009; 15:323–5.
    pmc: PMC2657634pubmed: 19193285
  11. Corniou B, Ardoin P, Bartholomew C. First isolation of a South American strain of eastern equine virus from a case of encephalitis in Trinidad. Trop Geogr Med 1972; 24:162–7.
    pubmed: 5037688
  12. Alice FJ. Infeccao humana pelo virus “leste” da encefalite equina. Bol Inst Biol da Bahia (Brazil) 1956; 3:3–9.
  13. Aguilar PV, Robich RM, Turell MJ. Endemic eastern equine encephalitis in the Amazon region of Peru. Am J Trop Med Hyg 2007; 76:293–8.
    pubmed: 17297038
  14. Arrigo NC, Adams AP, Weaver SC. Evolutionary patterns of eastern equine encephalitis virus in North versus South America suggest ecological differences and taxonomic revision. J Virol 2010; 84:1014–25.
    pmc: PMC2798374pubmed: 19889755
  15. Carrera JP, Cucunuba ZM, Neira K. Endemic and epidemic human alphavirus infections in Eastern Panama, an analysis of population-based cross-sectional surveys. bioRxiv 901462 [Preprint]. 10 January 2020.
    doi: 10.1101/2020.01.10.901462pmc: PMC7695115pubmed: 33124532google scholar: lookup
  16. Beaty BJ, Calisher CH, Shope RE. Arboviruses. In: Schmidt NJ, Emmons RW, eds. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. Washington, DC: American Public Health Association; 1989:797–855.
  17. Johnson BW, Kosoy O, Wang E. Use of sindbis/eastern equine encephalitis chimeric viruses in plaque reduction neutralization tests for arboviral disease diagnostics. Clin Vaccine Immunol 2011; 18:1486–91.
    pmc: PMC3165225pubmed: 21752946
  18. Quiroz E, Aguilar PV, Cisneros J. Venezuelan equine encephalitis in Panama: fatal endemic disease and genetic diversity of etiologic viral strains. PLoS Neglect Trop Dis 2009; 3:e472.
    pmc: PMC2697379pubmed: 19564908
  19. Chien YW, Liu ZH, Tseng FC. Prolonged persistence of IgM against dengue virus detected by commonly used commercial assays. BMC Infect Dis 2018; 18:156.
    pmc: PMC5880084pubmed: 29609533
  20. Pittman PR, Liu CT, Cannon TL. Immune interference after sequential alphavirus vaccine vaccinations. Vaccine 2009; 27:4879–82.
    pubmed: 19576665
  21. Calisher CH, Sasso DR, Sather GE. Possible evidence for interference with Venezuelan equine encephalitis virus vaccination of equines by pre-existing antibody to eastern or western equine encephalitis virus, or both. Appl Microbiol 1973; 26:485–8.
    pmc: PMC379832pubmed: 4751797
  22. Cole FE Jr, McKinney RW. Cross-protection in hamsters immunized with group A arbovirus vaccines. Infect Immun 1971; 4:37–43.
    pmc: PMC416261pubmed: 5154876
  23. Webb EM, Azar SR, Haller SL. Effects of Chikungunya virus immunity on Mayaro virus disease and epidemic potential. Scientific Reports 2019; 9:20399.
    pmc: PMC6938517pubmed: 31892710
  24. Linn ML, Mateo L, Gardner J, Suhrbier A. Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J Virol 1998; 72:5146–53.
    pmc: PMC110085pubmed: 9573286
  25. Coursaget P, Leboulleux D, Soumare M. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994; 21:250–4.
    pubmed: 7989718
  26. León CA. Sequelae of Venezuelan equine encephalitis in humans: a four year follow-up. Int J Epidemiol 1975; 4:131–40.
    pubmed: 1165151
  27. Greene IP, Paessler S, Austgen L. Envelope glycoprotein mutations mediate equine amplification and virulence of epizootic Venezuelan equine encephalitis virus. J Virol 2005; 79:9128–33.
    pmc: PMC1168750pubmed: 15994807
  28. Hollister AC, Longshore WA, Dean BH, Stevens IM. The 1952 outbreak of encephalitis in California; epidemiologic aspects. Calif Med 1953; 79:80–90.
    pmc: PMC1522013pubmed: 13067018
  29. Murray KO, Nolan MS, Ronca SE. The neurocognitive and MRI outcomes of West Nile virus infection: preliminary analysis using an external control group. Front Neurol 2018; 9:111.
    pmc: PMC5880927pubmed: 29636722
  30. Samaan Z, Vaz SM, Bawor M. Neuropsychological impact of West Nile virus infection: an extensive neuropsychiatric assessment of 49 cases in Canada. PLoS One 2016; 11:e0158364.
    pmc: PMC4924871pubmed: 27352145
  31. Ronca SE, Dineley KT, Paessler S. Neurological sequelae resulting from encephalitic alphavirus infection. Front Microbiol 2016; 7:959.
    pmc: PMC4913092pubmed: 27379085
  32. Murray KO, Garcia MN, Rahbar MH. Survival analysis, long-term outcomes, and percentage of recovery up to 8 years post-infection among the Houston West Nile virus cohort. PLoS One 2014; 9:e102953.
    pmc: PMC4108377pubmed: 25054656
  33. Bowen GS, Calisher CH. Virological and serological studies of Venezuelan equine encephalomyelitis in humans. J Clin Microbiol 1976; 4:22–7.
    pmc: PMC274383pubmed: 956360

Citations

This article has been cited 11 times.
  1. Corrales R, Díaz Y, Pineda V, Pitti Y, Saenz L, Carrera JP, Aguilar C, Martínez A, Chen-Germán M, Hanley KA, Vasilakis N, Tesh RB, Saldaña A, López-Vergès S. Seroprevalence of Arboviruses and Genetic Characterization of Orbiviruses in Sloths from Western Panama. Viruses 2025 Nov 17;17(11).
    doi: 10.3390/v17111507pubmed: 41305528google scholar: lookup
  2. Fassola LA, Rupil LL, Martínez F, Albrieu-Llinás G, Serradell MDC. Induction of systemic and mucosal immune response against Zika virus by vaccination with non-infectious chimeric VLPs. Sci Rep 2025 Jul 10;15(1):24834.
    doi: 10.1038/s41598-025-07059-6pubmed: 40640219google scholar: lookup
  3. Woodson CM, Carney SK, Kehn-Hall K. Neuropathogenesis of Encephalitic Alphaviruses in Non-Human Primate and Mouse Models of Infection. Pathogens 2025 Feb 14;14(2).
    doi: 10.3390/pathogens14020193pubmed: 40005568google scholar: lookup
  4. Rivera LF, Lezcano-Coba C, Galué J, Rodriguez X, Juarez Y, de Souza WM, Capitan-Barrios Z, Valderrama A, Abrego L, Cedeño H, Jackman C, Waggoner JJ, Aguilar PV, Guzman H, Weaver SC, Tesh RB, López-Vèrges S, Donnelly CA, Estofolete CF, Nogueira ML, Faria NR, Vasilakis N, Vittor AY, Smith DR, Carrera JP. Characteristics of Madariaga and Venezuelan Equine Encephalitis Virus Infections, Panama. Emerg Infect Dis 2024;30(14):94-104.
    doi: 10.3201/eid3014.240182pubmed: 39530903google scholar: lookup
  5. Rueda Altez MS, Kimberlin DW. The dynamic landscape of emerging viral infections. Pediatr Res 2024 Jan;95(2):411-413.
    doi: 10.1038/s41390-023-02974-8pubmed: 38135723google scholar: lookup
  6. Carrera J-P, Araúz D, Rojas A, Cardozo F, Stittleburg V, Morales Claro I, Galue J, Lezcano-Coba C, Romero Rebello Moreira F, -Rivera LF, Chen-Germán M, Moreno B, Capitan-Barrios Z, López-Vergès S, Pascale JM, Sabino EC, Valderrama A, Hanley KA, Donnelly CA, Vasilakis N, Faria NR, Waggoner JJ. Real-time RT-PCR for Venezuelan equine encephalitis complex, Madariaga, and Eastern equine encephalitis viruses: application in human and mosquito public health surveillance in Panama. J Clin Microbiol 2023 Dec 19;61(12):e0015223.
    doi: 10.1128/jcm.00152-23pubmed: 37982611google scholar: lookup
  7. Carrera JP, Galué J, de Souza WM, Torres-Cosme R, Lezcano-Coba C, Cumbrera A, Vasilakis N, Tesh RB, Guzman H, Weaver SC, Vittor AY, Samudio R, Miguel Pascale J, Valderrama A, Cáceres Carrera L, Donnelly CA, Faria NR. Madariaga and Venezuelan equine encephalitis virus seroprevalence in rodent enzootic hosts in Eastern and Western Panama. bioRxiv 2023 Aug 29;.
    doi: 10.1101/2023.08.28.555226pubmed: 37693579google scholar: lookup
  8. Kafai NM, Janova H, Cain MD, Alippe Y, Muraro S, Sariol A, Elam-Noll M, Klein RS, Diamond MS. Entry receptor LDLRAD3 is required for Venezuelan equine encephalitis virus peripheral infection and neurotropism leading to pathogenesis in mice. Cell Rep 2023 Aug 29;42(8):112946.
    doi: 10.1016/j.celrep.2023.112946pubmed: 37556325google scholar: lookup
  9. Bonilla-Aldana DK, Bonilla Carvajal CD, Moreno-Ramos E, Barboza JJ, Rodriguez-Morales AJ. Mapping Eastern (EEE) and Venezuelan Equine Encephalitides (VEE) among Equines Using Geographical Information Systems, Colombia, 2008-2019. Viruses 2023 Mar 8;15(3).
    doi: 10.3390/v15030707pubmed: 36992416google scholar: lookup
  10. Ortiz DI, Piche-Ovares M, Romero-Vega LM, Wagman J, Troyo A. The Impact of Deforestation, Urbanization, and Changing Land Use Patterns on the Ecology of Mosquito and Tick-Borne Diseases in Central America. Insects 2021 Dec 23;13(1).
    doi: 10.3390/insects13010020pubmed: 35055864google scholar: lookup
  11. Calvert AE, Bennett SL, Hunt AR, Fong RH, Doranz BJ, Roehrig JT, Blair CD. Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection. Virology 2022 Jan 2;565:13-21.
    doi: 10.1016/j.virol.2021.09.007pubmed: 34626907google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.